Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence

Petru, Edgar; Sevin, Bernd Uwe; Perras, James P.; Boike, Guy M.; Ramos, Reinaldo; Nguyen, Hoa N.; Averette, H.E.

doi:10.1016/0090-8258(90)90032-g

Cited by 48 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…44X,der (X)t(X;1)(q12;q11), -1,der (1)t(1;3)(p36;p26),der(6)t (1;6)(q21;q22), ins(8;1)(p22;p22p36),-13, der (14)t(14;20) (p12;p112.2), der(15)t(15;20)(p12;p12.2),add (22)(p11) [22].…”

Section: Resultsunclassified

“…3A). SKOV-3 and OVCAR-8 are derived from metastatic tumors of patients previously treated with chemotherapy (21,22). HEY was derived from a peritoneal deposit of a patient with a moderately differentiated papillary cystadenocarcinoma (23), and BG-1 was derived from the solid primary tumor tissue from an untreated patient with stage III, very poorly differentiated ovarian adenocarcinoma (24).…”

Section: Resultsmentioning

confidence: 99%

“…In this context, it is important to note that CAOV-3 and OVCAR-3 ovarian cancer cells, which are also resistant to cisplatin (22,33), express autocrine IGF-I (34). Likewise, cisplatin-resistant SKOV-3 (22) and OVCAR-4 (35) cells express both IGF-I and the IGF-IR (36, 37). Taken together, these results provide strong evidence for an essential role of the IGF-IR signaling pathway for cisplatin resistance in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Eckstein

Servan

Hildebrandt³

et al. 2009

Cancer Research

143

127

View full text Add to dashboard Cite

Platinum plays a central role in the therapy of ovarian cancer, and the emergence of platinum resistance is a major obstacle for clinical management of the disease. We treated A2780 ovarian cancer cells by weekly cycles of cisplatin over a period of 6 months and unveiled that enhanced insulin-like growth factor I receptor (IGF-IR) expression and autocrine IGF-I are associated with hyperactivation of the IGF-IR and phosphatidylinositol-3-OH kinase (PI3K) pathways in cisplatinresistant cells. IGF-IR expression levels increased during treatment cycles and correlated with cisplatin resistance. Purified IGF-I induced cisplatin resistance in diverse ovarian cancer cell lines, and small molecule inhibitors proved that IGF-IR and PI3K are essential for cisplatin resistance. Similar results were obtained with BG-1 ovarian cancer cells. Cytogenetic and array comparative genomic hybridization analyses revealed selection and de novo formation of chromosomal alterations during resistance development. An analysis of gene expression profiles of primary ovarian carcinomas identified the regulatory subunit PIK3R2 of PI3-kinase as a significant negative prognosis factor for ovarian cancer. We conclude that targeting the IGF-IR and the PI3K pathways is a promising new strategy to treat cisplatinresistant ovarian carcinomas.

show abstract

“…44X,der (X)t(X;1)(q12;q11), -1,der (1)t(1;3)(p36;p26),der(6)t (1;6)(q21;q22), ins(8;1)(p22;p22p36),-13, der (14)t(14;20) (p12;p112.2), der(15)t(15;20)(p12;p12.2),add (22)(p11) [22].…”

Section: Resultsunclassified

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Eckstein

Servan

Hildebrandt³

et al. 2009

Cancer Research

143

127

View full text Add to dashboard Cite

show abstract

“…Similar to plasma, such compounds are known to evoke oxidative stress [70]. For regular chemotherapeutic agents, SKOV-3 are more resistant compared to OVCAR-3 [71]. …”

Section: Discussionmentioning

confidence: 99%

Plasma Treatment of Ovarian Cancer Cells Mitigates Their Immuno-Modulatory Products Active on THP-1 Monocytes

Bekeschus

Wulf

Freund

et al. 2018

Plasma

View full text Add to dashboard Cite

Cancers modulate their microenvironment to favor their growth. In particular, monocytes and macrophages are targeted by immuno-modulatory molecules installed by adjacent tumor cells such as ovarian carcinomas. Cold physical plasma has recently gained attention as innovative tumor therapy. We confirmed this for the OVCAR-3 and SKOV-3 ovarian cancer cell lines in a caspase 3/7 independent and dependent manner, respectively. To elaborate whether plasma exposure interferes with their immunomodulatory properties, supernatants of control and plasma-treated tumor cells were added to human THP-1 monocyte cultures. In the latter, modest effects on intracellular oxidation or short-term metabolic activity were observed. By contrast, supernatants of plasma-treated cancer cells abrogated significant changes in morphological and phenotypic features of THP-1 cells compared to those cultured with supernatants of non-treated tumor cell counterparts. This included cell motility and morphology, and modulated expression patterns of nine cell surface markers known to be involved in monocyte activation. This was particularly pronounced in SKOV-3 cells. Further analysis of tumor cell supernatants indicated roles of small particles and interleukin 8 and 18, with MCP1 presumably driving activation in monocytes. Altogether, our results suggest plasma treatment to alleviate immunomodulatory secretory products of ovarian cancer cells is important for driving a distinct myeloid cell phenotype.

show abstract

“…In this assay, luciferin and luciferase are added to media and in the presence of ATP, luciferin is oxidized giving off light that can be measured using a luminometer or a CCD camera. These assays are a direct measure of cell viability and can be used to assess cell proliferation and cytotoxicity in vitro (Garewal, Ahmann et al 1986;Kuzmits, Aiginger et al 1986;Kuzmits, Rumpold et al 1986;Ahmann, Garewal et al 1987;Sevin, Peng et al 1988;Petru, Sevin et al 1990;Crouch, Kozlowski et al 1993). Using the ATP assay Garewal et al were able to distinguish between cytostatic and cytotoxic effects of therapeutics on a colon cancer cell line in vitro (Garewal, Ahmann et al 1986).…”

Section: Use Of Bli In Oncology Researchmentioning

confidence: 99%

Bioluminescence Applications in Preclinical Oncology Research

Kalra¹,

Bally²

2012

Bioluminescence - Recent Advances in Oceanic Measurements and Laboratory Applications

View full text Add to dashboard Cite

Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence

Cited by 48 publications

References 12 publications

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

Plasma Treatment of Ovarian Cancer Cells Mitigates Their Immuno-Modulatory Products Active on THP-1 Monocytes

Bioluminescence Applications in Preclinical Oncology Research

Contact Info

Product

Resources

About